Literature DB >> 31895947

Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors.

Paolo Strati1, Ellen J Schlette2, Luisa M Solis Soto3, Daniela E Duenas3, Mariela Sivina4, Ekaterina Kim4, Michael J Keating4, William G Wierda4, Alessandra Ferrajoli4, Hagop Kantarjian4, Zeev Estrov4, Nitin Jain4, Philip A Thompson4, Ignacio I Wistuba3, Jan A Burger4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31895947      PMCID： PMC7019190          DOI： 10.1182/blood.2019003570

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  6 in total

Review 1.  Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.

Authors:  Natalia Timofeeva; Varsha Gandhi
Journal:  Blood Cancer J       Date:  2021-04-29       Impact factor: 11.037

Review 2.  Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.

Authors:  Prithviraj Bose; Varsha Gandhi
Journal:  Fac Rev       Date:  2021-02-26

3.  Janus kinases restrain chronic lymphocytic leukemia cells in patients on ibrutinib: Results of a phase II trial.

Authors:  David E Spaner; Yuxuan Luo; Guizhei Wang; Jennifer Gallagher; Hubert Tsui; Yonghong Shi
Journal:  Cancer Med       Date:  2021-11-17       Impact factor: 4.452

4.  Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study.

Authors:  Francesca Romana Mauro; Francesca Paoloni; Stefano Molica; Gianluigi Reda; Livio Trentin; Paolo Sportoletti; Monia Marchetti; Daniela Pietrasanta; Roberto Marasca; Gianluca Gaidano; Marta Coscia; Caterina Stelitano; Donato Mannina; Nicola Di Renzo; Fiorella Ilariucci; Anna Marina Liberati; Lorella Orsucci; Francesca Re; Monica Tani; Gerardo Musuraca; Daniela Gottardi; Pier Luigi Zinzani; Alessandro Gozzetti; Annalia Molinari; Massimo Gentile; Annalisa Chiarenza; Luca Laurenti; Marzia Varettoni; Adalberto Ibatici; Roberta Murru; Valeria Ruocco; Ilaria Del Giudice; Maria Stefania De Propris; Irene Della Starza; Sara Raponi; Mauro Nanni; Paola Fazi; Antonino Neri; Anna Guarini; Gian Matteo Rigolin; Alfonso Piciocchi; Antonio Cuneo; Robin Foà
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

Review 5.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

6.  A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Xin Tian; Shakuntala Rampertaap; Rui Mu; Susan Soto; Jeanine Superata; Erika Gaglione; Clare Sun; Jennifer Lotter; Maryalice Stetler-Stevenson; Constance M Yuan; Irina Maric; Stefania Pittaluga; Sergio Rosenzweig; Thomas Fleisher; Adrian Wiestner; Inhye E Ahn
Journal:  Am J Hematol       Date:  2020-09-08       Impact factor: 13.265
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.